Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson On Track For Eight NME Filings, Approvals In 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm plans to submit a follow-on to the recently approved antipsychotic Invega by year-end.

You may also be interested in...



Cell Therapeutics Gets In The Groove With Systems Medicine Acquisition

Johnson & Johnson’s Yondelis is in competition with Systems Medicine’s brostallicin to become first minor groove binding agent on the market.

Cell Therapeutics Gets In The Groove With Systems Medicine Acquisition

Johnson & Johnson’s Yondelis is in competition with Systems Medicine’s brostallicin to become first minor groove binding agent on the market.

J&J Seeks Approval For Doxil Plus Velcade In Multiple Myeloma

Supplemental claim for liposomal doxorubicin has a May 21 priority review date, J&J’s Ortho Biotech unit tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel